Total Payments
$2,462
2024 Payments
$305.99
Companies
14
Transactions
42
Medicare Patients
1,770
Medicare Billing
$252,439
Payment Breakdown by Category
Food & Beverage$2,271 (92.2%)
Education$191.24 (7.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,271 | 40 | 92.2% |
| Education | $191.24 | 2 | 7.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $472.45 | 9 | $0 (2023) |
| Lilly USA, LLC | $339.81 | 12 | $0 (2018) |
| Incyte Corporation | $338.52 | 3 | $0 (2023) |
| Celgene Corporation | $232.45 | 2 | $0 (2019) |
| Astellas Pharma US Inc | $199.32 | 2 | $0 (2024) |
| GlaxoSmithKline, LLC. | $127.77 | 2 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $122.26 | 1 | $0 (2017) |
| Apellis Pharmaceuticals, Inc. | $119.27 | 1 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $118.63 | 2 | $0 (2024) |
| PFIZER INC. | $111.68 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $305.99 | 3 | Apellis Pharmaceuticals, Inc. ($119.27) |
| 2023 | $507.82 | 5 | Janssen Biotech, Inc. ($248.69) |
| 2022 | $127.77 | 2 | GlaxoSmithKline, LLC. ($127.77) |
| 2021 | $153.45 | 6 | Janssen Biotech, Inc. ($153.45) |
| 2020 | $70.31 | 1 | Janssen Biotech, Inc. ($70.31) |
| 2019 | $114.32 | 1 | Celgene Corporation ($114.32) |
| 2018 | $634.35 | 11 | Lilly USA, LLC ($260.45) |
| 2017 | $548.03 | 13 | E.R. Squibb & Sons, L.L.C. ($122.26) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/01/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $98.00 | General |
| 04/05/2024 | Janssen Scientific Affairs, LLC | TECVAYLI (Biological), TALVEY, CARVYKTI | Food and Beverage | In-kind items and services | $88.72 | General |
| Category: Oncology | ||||||
| 01/24/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $119.27 | General |
| Category: Hematology | ||||||
| 12/11/2023 | Janssen Scientific Affairs, LLC | DARZALEX (Drug) | Food and Beverage | In-kind items and services | $29.91 | General |
| Category: Oncology | ||||||
| 11/02/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $101.32 | General |
| Category: Oncology | ||||||
| 10/12/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Food and Beverage | In-kind items and services | $124.70 | General |
| Category: Oncology | ||||||
| 04/05/2023 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $123.99 | General |
| Category: Oncology | ||||||
| 02/08/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $127.90 | General |
| Category: Hematology/Oncology | ||||||
| 09/20/2022 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $5.19 | General |
| Category: ONCOLOGY | ||||||
| 03/10/2022 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $122.58 | General |
| Category: ONCOLOGY | ||||||
| 12/29/2021 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $1.77 | General |
| Category: Oncology | ||||||
| 12/29/2021 | Janssen Biotech, Inc. | DARZALEX (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $1.49 | General |
| Category: Oncology | ||||||
| 12/06/2021 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $3.11 | General |
| Category: Oncology | ||||||
| 09/28/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $133.78 | General |
| Category: Oncology | ||||||
| 06/28/2021 | Janssen Biotech, Inc. | DARZALEX (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $3.44 | General |
| Category: Oncology | ||||||
| 04/09/2021 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $9.86 | General |
| Category: Oncology | ||||||
| 02/26/2020 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $70.31 | General |
| Category: Oncology | ||||||
| 08/06/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $114.32 | General |
| Category: Hematology / Oncology | ||||||
| 12/13/2018 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $14.23 | General |
| 11/13/2018 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $113.60 | General |
| 08/27/2018 | Lilly USA, LLC | — | Education | In-kind items and services | $93.24 | General |
| 08/20/2018 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $35.06 | General |
| 08/20/2018 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $35.06 | General |
| 08/16/2018 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $11.41 | General |
| Category: Oncology | ||||||
| 06/12/2018 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $118.13 | General |
| Category: Hematology / Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 384 | 762 | $182,704 | $64,111 |
| 2022 | 11 | 449 | 850 | $191,236 | $66,920 |
| 2021 | 10 | 439 | 797 | $174,670 | $62,360 |
| 2020 | 12 | 498 | 894 | $191,374 | $59,048 |
Total Patients
1,770
Total Services
3,303
Medicare Billing
$252,439
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 88 | 321 | $89,880 | $32,951 | 36.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 144 | 197 | $41,173 | $11,680 | 28.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 72 | $14,472 | $6,458 | 44.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 28 | $10,976 | $3,719 | 33.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 31 | 31 | $8,277 | $2,855 | 34.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 37 | $5,143 | $2,241 | 43.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 21 | 23 | $4,761 | $2,014 | 42.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $7,182 | $1,901 | 26.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 12 | 35 | $840.00 | $294.00 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 192 | 329 | $68,761 | $21,808 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 76 | 192 | $53,760 | $20,530 | 38.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 32 | 114 | $22,914 | $8,561 | 37.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 33 | $12,936 | $4,918 | 38.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 30 | 30 | $8,010 | $3,011 | 37.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 26 | 29 | $6,003 | $2,181 | 36.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 33 | $4,587 | $1,770 | 38.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 18 | 18 | $5,796 | $1,472 | 25.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $4,389 | $1,402 | 31.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 14 | 17 | $3,024 | $1,136 | 37.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 11 | 44 | $1,056 | $130.92 | 12.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 190 | 372 | $77,748 | $25,869 | 33.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 43 | 131 | $26,331 | $10,571 | 40.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 40 | 88 | $24,640 | $9,379 | 38.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 26 | 31 | $12,152 | $4,959 | 40.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 31 | 31 | $8,277 | $3,467 | 41.9% |
About Dr. Rex Garland, D.O
Dr. Rex Garland, D.O is a Hematology & Oncology healthcare provider based in Temple, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/06/2013. The National Provider Identifier (NPI) number assigned to this provider is 1902241813.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rex Garland, D.O has received a total of $2,462 in payments from pharmaceutical and medical device companies, with $305.99 received in 2024. These payments were reported across 42 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($2,271).
As a Medicare-enrolled provider, Garland has provided services to 1,770 Medicare beneficiaries, totaling 3,303 services with total Medicare billing of $252,439. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location Temple, TX
- Active Since 05/06/2013
- Last Updated 12/17/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1902241813
Products in Payments
- Revlimid (Drug) $232.45
- JAKAFI (Drug) $227.90
- TECVAYLI (Biological) $212.71
- DARZALEX (Biological) $209.75
- IMBRUVICA (Drug) $133.78
- BLENREP (Biological) $127.77
- OPDIVO (Biological) $122.26
- Empaveli (Drug) $119.27
- XTANDI (Drug) $111.68
- Xospata (Drug) $101.32
- SOLIRIS (Drug) $100.00
- Onivyde (Drug) $75.03
- CYRAMZA (Drug) $71.10
- DARZALEX (Drug) $34.84
- VERZENIO (Drug) $22.30
- Perjeta (Biological) $19.92
- ALIMTA (Drug) $13.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Temple
Dr. Lucas Wong, M.d, M.D
Hematology & Oncology — Payments: $13,938
Hematology & Oncology $13,938
Dr. Juan Posada, M.d, M.D
Hematology & Oncology — Payments: $2,473
Hematology & Oncology $2,473
Dr. Sripriya Santhanam, M.d, M.D
Hematology & Oncology — Payments: $1,164
Hematology & Oncology $1,164
Khine Oo, M.d, M.D
Hematology & Oncology — Payments: $12.56
Hematology & Oncology $12.56
Dr. Daniel Hadlock, M.d, M.D
Hematology & Oncology
Hematology & Oncology
Dr. Eliseo Hervas, M.d, M.D
Hematology & Oncology
Hematology & Oncology